Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14396751 | 0.94 | CETP (0.39) | MAPTCETPHDAC1HDAC6ACHE | |
| SCHEMBL13009752 | 0.91 | MAPT (0.42) | LPAR1LPAR5MAPTACHELMNA | |
| SCHEMBL13009801 | 0.87 | CETP (0.44) | MAPTCETPACHEPDE6DLMNA | |
| SCHEMBL13009787 | 0.86 | LMNA (0.38) | NR1H4MAPTCETPACHEPDE6D | |
| SCHEMBL13009809 | 0.86 | MAPT (0.44) | LPAR1LPAR5MAPTCETPACHE | |
| SCHEMBL13009844 | 0.85 | MAPT (0.40) | LPAR1LPAR5NR1H4MAPTCETP | |
| SCHEMBL5275145 | 0.85 | LPAR1 (0.43) | LPAR1LPAR5S1PR1 | |
| SCHEMBL13009701 | 0.85 | MAPT (0.43) | MAPTCETPACHEPDE6DLMNA | |
| SCHEMBL13009738 | 0.85 | MAPT (0.43) | LPAR1LPAR5MAPTCETPACHE | |
| SCHEMBL13009794 | 0.85 | MAPT (0.42) | NR1H4MAPTCETPACHEESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939989-B2 | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040082658-A1 | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082658-A1 | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BCAT2, BCAT1, AADAT | LPAR1 4651/4885LPAR5 4393/4885NR1H4 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.